Alivus Life Sciences Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report.
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences) concluded a postal ballot conducted entirely through remote e-voting between June 25 and July 24, 2025. Two special resolutions were put to shareholders, both relating to the re-appointment of independent directors. Resolution 1 sought the re-appointment of Mrs. Manju Agarwal (DIN 06921105) and was passed with 95.92% votes in favour and 4.08% against. Resolution 2 sought the re-appointment of Mr. Taruvai Laxminarayanan Easwar (DIN 03135959) and was passed with an overwhelming 99.95% in favour and just 0.05% against. In total, about 10.52 crore shares were voted, representing roughly 85.8% of outstanding shares. Promoters voted 100% in favour of both resolutions. The scrutinizer, Mr. Bhadresh Shah, confirmed both resolutions were duly passed with the requisite majority.
Both independent directors have been re-appointed, ensuring continuity on the board. The very high approval (especially 99.95% for Mr. Easwar) shows strong shareholder support, and this routine governance outcome is unlikely to move the stock price.